Clinical Trials Browser

INDUSTRY × Lymphoma, Non-Hodgkin × blinatumomab × Clear all

NCT02961881 2024-02-02

A Phase 1b Open-Label Study Investigating the Safety and Pharmacokinetics of Administration of Subcutaneous Blinatumomab for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma

Phase 1 Completed

35 enrolled 27 charts

Lymphoma, Non-Hodgkin

NCT01741792 2017-01-06

Clinical Study With Blinatumomab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Phase 2 Completed

25 enrolled 18 charts

Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Lymphoma, Large B-Cell, Diffuse

NCT00274742 2015-01-16

Safety Study of the Bispecific T-cell Engager Blinatumomab (MT103) in Patients With Relapsed NHL

Phase 1 Completed

76 enrolled 15 charts

Bites and Stings, Lymphoma, Non-Hodgkin, Recurrence

NCT00538096 2008-09-05

A Phase I Study to Evaluate Safety, Tolerability in Adults With Lymphoma

Phase 1 Withdrawn

Lymphoma, Non-Hodgkin, Lymphoma, B-Cell